 On Monday, Opko Health Inc. NASDAQ:OPK shares edged slightly higher after Jefferies and Piper Sandler analysts issued upbeat statements following Fridays decline. The OPK stock price slipped more than 4 after it announced that the Food and Drug Administration FDA had extended the review period for the Biologics License Application BLA for Somatrogon. 